Characterization of Clinical Isolates ofKlebsiella pneumoniae from 19 Laboratories Using the National Committee for Clinical Laboratory Standards Extended-Spectrum β-Lactamase Detection Methods
暂无分享,去创建一个
A. Oliver | J. Mcgowan | F. Tenover | J. Rasheed | Gregory J. Anderson | Christine D. Steward | G. Anderson | J. Biddle | C. Steward | P. Raney | P. Williams | S. Hubert | Kelley L. Brittain | Susannah K. Hubert
[1] K. Kaye,et al. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. , 2004, Infectious disease clinics of North America.
[2] P. Nordmann,et al. Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae. , 2001, The Journal of antimicrobial chemotherapy.
[3] P. Nordmann,et al. OXA-28, an Extended-Spectrum Variant of OXA-10 β-Lactamase from Pseudomonas aeruginosa and Its Plasmid- and Integron-Located Gene , 2001, Antimicrobial Agents and Chemotherapy.
[4] A. Oliver,et al. Nucleotide Sequence and Characterization of a Novel Cefotaxime-Hydrolyzing β-Lactamase (CTX-M-10) Isolated in Spain , 2001, Antimicrobial Agents and Chemotherapy.
[5] P. Nordmann,et al. Plasmid-Mediated Cephalosporinase ACC-1 in Clinical Isolates of Proteus mirabilis and Escherichia coli , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[6] A. Oliver,et al. Molecular Characterization of FOX-4, a New AmpC-Type Plasmid-Mediated β-Lactamase from an Escherichia coli Strain Isolated in Spain , 2000, Antimicrobial Agents and Chemotherapy.
[7] K. Kaye,et al. PATHOGENS RESISTANT TO ANTIMICROBIAL AGENTS , 2000 .
[8] P. Coudron,et al. Occurrence and Detection of AmpC Beta-Lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates at a Veterans Medical Center , 2000, Journal of Clinical Microbiology.
[9] L. Tzouvelekis,et al. CTX-M-type β-lactamases: an emerging group of extended-spectrum enzymes , 2000 .
[10] L. Rice,et al. High-Level Expression of Chromosomally Encoded SHV-1 β-Lactamase and an Outer Membrane Protein Change Confer Resistance to Ceftazidime and Piperacillin- Tazobactam in a Clinical Isolate of Klebsiella pneumoniae , 2000, Antimicrobial Agents and Chemotherapy.
[11] P. Nordmann,et al. OXA-type beta-lactamases. , 1999, Current pharmaceutical design.
[12] R. Gaynes,et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] G. Jacoby,et al. Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.
[14] L. Rice,et al. Inhibitor resistant class A beta-lactamases. , 1999, Frontiers in bioscience : a journal and virtual library.
[15] G. Paul,et al. Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. , 1999, The Journal of antimicrobial chemotherapy.
[16] P. Nordmann,et al. Trends in β-Lactam Resistance Among Enterobacteriaceae , 1998 .
[17] L. Martínez-Martínez,et al. Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae Isolates from Clinical Samples and Activities of Cephalosporins and Carbapenems , 1998, Antimicrobial Agents and Chemotherapy.
[18] L. Bret,et al. Chromosomally Encoded AmpC-Type β-Lactamase in a Clinical Isolate of Proteus mirabilis , 1998, Antimicrobial Agents and Chemotherapy.
[19] G. French,et al. Mechanism and stability of hyperproduction of the extended-spectrum beta-lactamase SHV-5 in Klebsiella pneumoniae. , 1997, The Journal of antimicrobial chemotherapy.
[20] P. Nordmann,et al. OXA-18, a class D clavulanic acid-inhibited extended-spectrum beta-lactamase from Pseudomonas aeruginosa , 1997, Antimicrobial agents and chemotherapy.
[21] F. Kayser,et al. Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12 , 1997, Antimicrobial agents and chemotherapy.
[22] M. Gazouli,et al. Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant , 1997, Antimicrobial agents and chemotherapy.
[23] A. Medeiros,et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia , 1997, Antimicrobial agents and chemotherapy.
[24] R. Gaynes,et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] G L French,et al. Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase , 1996, Journal of clinical microbiology.
[26] G. Jacoby,et al. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins , 1996, Antimicrobial agents and chemotherapy.
[27] I. Stemplinger,et al. Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases , 1996, Antimicrobial agents and chemotherapy.
[28] Sanders Cc. In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. , 1996 .
[29] D. Livermore. beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.
[30] D H Persing,et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.
[31] G. Jacoby,et al. A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.
[32] S. B. Singer,et al. Effective cooling allows sonication to be used for liberation of beta-lactamases from gram negative bacteria. , 1989, The Journal of antimicrobial chemotherapy.
[33] J. Frère,et al. Sequence and comparative analysis of three Enterobacter cloacae ampC beta-lactamase genes and their products. , 1988, The Biochemical journal.
[34] P Huovinen,et al. Sequence of PSE-2 beta-lactamase , 1988, Antimicrobial Agents and Chemotherapy.
[35] P. H. Roy,et al. Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[36] S. Normark,et al. Sequence of the Citrobacter freundii OS60 chromosomal ampCβ‐lactamase gene , 1986 .
[37] J. W. Dale,et al. Sequence of the OXA2 β‐lactamase: comparison with other penicillin‐reactive enzymes , 1985, FEBS letters.
[38] T. Grundström,et al. ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[39] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[40] A. Harris,et al. The use of analytical isoelectric focusing for detection and identification of beta-lactamases. , 1975, Journal of general microbiology.
[41] M J Ferraro. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[42] David M. Livermore,et al. b-Lactamases in Laboratory and Clinical Resistance , 1995 .
[43] D. Persing,et al. Diagnostic molecular microbiology : principles and applications , 1993 .